{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/IRLA",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# IRulya Therapeutics Inc. (NASDAQ: IRLA) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is IRulya Therapeutics Inc., listed on NASDAQ under ticker IRLA, with ISIN US22053A3059. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). The security type is Corporate, the sector is 2836 Biological Products, (No Diagnostic Substances), and the jurisdiction is United States, Delaware. The segment is not on the record. The listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 80 filings in the twelve months to 2026-11-08, across 47 filing days. The median gap between filing days is 5.0 days. The latest filing is dated 2026-11-05, 3 days before the record date, and is of type regulatory_filing. The NASDAQ exchange median is 6.0 days for cadence gap, 52 filings and 5.0 days latency across 4,359 issuers. The sector median is 5.5 days for cadence gap, 65.5 filings and 4.0 days latency across 176 issuers. The window holds 21 regulatory_filing, 21 directors_dealings, 9 corporate_news, 7 agm_egm, 7 director_change, 7 results, 3 ad_hoc, 2 halt_suspension, 2 prospectus and 1 takeover filing.\n\n## Auditor\n\nThe auditor of record is BDO USA, P.C., located in San Jose, California. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable, because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nNo research houses were found on the issuer's investor-relations pages read. The count is 0.\n\n## Open research\n\nNo openly published research notes were found on the record. The count is 0.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer is sealed for the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001662774.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/IRLA (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/IRLA (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm",
    "state": "sourced",
    "value": "BDO USA, P.C."
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm",
    "state": "sourced",
    "value": "243"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm",
    "state": "sourced",
    "value": "San Jose, California"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/IRLA",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 176,
     "median_cadence_gap_days": 5.5,
     "median_filings": 65.5,
     "median_latency_days": 4,
     "name": "2836 Biological Products, (No Diagnostic Substances)"
    }
   },
   "by_type": {
    "ad_hoc": 3,
    "agm_egm": 7,
    "corporate_news": 9,
    "director_change": 7,
    "directors_dealings": 21,
    "halt_suspension": 2,
    "prospectus": 2,
    "regulatory_filing": 21,
    "results": 7,
    "takeover": 1
   },
   "cadence_median_gap_days": 5,
   "filing_days": 47,
   "filings": 80,
   "latency_days": 3,
   "latest": [
    {
     "category": "144",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1662774/000162828026070962/xsl144X01/primary_doc.xml",
     "title": "144",
     "type": "regulatory_filing"
    },
    {
     "category": "144",
     "date": "2026-10-21",
     "source": "https://www.sec.gov/Archives/edgar/data/1662774/000162828026066751/xsl144X01/primary_doc.xml",
     "title": "144",
     "type": "regulatory_filing"
    },
    {
     "category": "3",
     "date": "2026-10-19",
     "source": "https://www.sec.gov/Archives/edgar/data/1662774/000215940726000002/xslF345X06/form3-10192026_081001.xml",
     "title": "3",
     "type": "directors_dealings"
    },
    {
     "category": "3",
     "date": "2026-10-19",
     "source": "https://www.sec.gov/Archives/edgar/data/1662774/000215939426000002/xslF345X06/form3-10192026_081042.xml",
     "title": "3",
     "type": "directors_dealings"
    },
    {
     "category": "3",
     "date": "2026-10-19",
     "source": "https://www.sec.gov/Archives/edgar/data/1662774/000215911726000002/xslF345X06/form3-10192026_081004.xml",
     "title": "3",
     "type": "directors_dealings"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/IRLA",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-14",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US22053A3059"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001662774.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001662774.json",
    "state": "sourced",
    "value": "IRulya Therapeutics Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001662774.json",
    "state": "sourced",
    "value": "2836 Biological Products, (No Diagnostic Substances)"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001662774.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "IRLA"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:76eb8197d5ba297e02e2e5178184e665e36c11e51f3acb1893c0876522e8cc33",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/IRLA",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:76eb8197d5ba297e02e2e5178184e665e36c11e51f3acb1893c0876522e8cc33",
 "path": "/us/NASDAQ/IRLA",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is IRulya Therapeutics Inc., listed on NASDAQ under ticker IRLA, with ISIN US22053A3059. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). The security type is Corporate, the sector is 2836 Biological Products, (No Diagnostic Substances), and the jurisdiction is United States, Delaware. The segment is not on the record. The listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 80 filings in the twelve months to 2026-11-08, across 47 filing days. The median gap between filing days is 5.0 days. The latest filing is dated 2026-11-05, 3 days before the record date, and is of type regulatory_filing. The NASDAQ exchange median is 6.0 days for cadence gap, 52 filings and 5.0 days latency across 4,359 issuers. The sector median is 5.5 days for cadence gap, 65.5 filings and 4.0 days latency across 176 issuers. The window holds 21 regulatory_filing, 21 directors_dealings, 9 corporate_news, 7 agm_egm, 7 director_change, 7 results, 3 ad_hoc, 2 halt_suspension, 2 prospectus and 1 takeover filing.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is BDO USA, P.C., located in San Jose, California. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the issuer's investor-relations pages read. The count is 0.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record. The count is 0.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer is sealed for the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001662774.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/IRLA"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/qncx-20251231.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/IRLA"
  }
 ],
 "title": "IRulya Therapeutics Inc. (IRLA) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}